Clinical Trial

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Name: Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea — clinical trial record (NCT06942156)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: OPTIMIZE-HTx

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.

Trial Details

NCT Number	NCT06942156
Lead Sponsor	Chong Kun Dang Pharmaceutical
Conditions	Heart Transplant
Enrollment	140 participants
Start Date	2025-08-14
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-04-24